Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 302

Results For "EY"

3097 News Found

Trials of three more vaccines are in advanced stage: Modi
News | June 08, 2021

Trials of three more vaccines are in advanced stage: Modi

The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age


Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).


Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
News | June 03, 2021

Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India

Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC


Lasa Supergenerics FY21 profit up 521%
News | June 02, 2021

Lasa Supergenerics FY21 profit up 521%

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%


Unilever to launch recyclable tubes for oral care in India
Packaging | June 01, 2021

Unilever to launch recyclable tubes for oral care in India

EPL will supply APR approved 100% recyclable and fully sustainable Platina Tubes for the toothpaste category of Unilever


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Zydus new initiative to safeguard patients against counterfeit drugs
News | May 29, 2021

Zydus new initiative to safeguard patients against counterfeit drugs

The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website


Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%
News | May 28, 2021

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%

The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year